REGEN BIOPHARMA, INC. (RGBP) Operating income 2017–2025
REGEN BIOPHARMA, INC. (RGBP) annual operating income history from SEC filings — each fiscal year as reported.
-$338,540FY2025 · since FY2017: -$2.5M → -$338,540
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$338,540 | +18.9% |
| FY2024 | -$417,221 | +39.3% |
| FY2023 | -$686,950 | -102.3% |
| FY2022 | -$339,605 | -69.2% |
| FY2021 | -$200,771 | +4.1% |
| FY2020 | -$209,317 | +72.3% |
| FY2019 | -$756,785 | +46.9% |
| FY2018 | -$1.4M | +43.2% |
| FY2017 | -$2.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBP financial trends
RGBP RevenueRGBP Net incomeRGBP Net marginRGBP Gross profitRGBP Gross marginRGBP Operating marginRGBP Operating cash flowRGBP Free cash flowRGBP Capital expendituresRGBP Return on equityRGBP Stock buybacksRGBP Dividends paidRGBP Total assetsRGBP Total liabilitiesRGBP Shareholders’ equityRGBP overview →